Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation

Blood

Volumn 121, Issue 15, 2013, Pages 3023-3032

  Fang, Chao ^a   Stavrou, Evi ^a   Schmaier, Alec A ^b   Grobe, Nadja ^c   Morris, Mariana ^c   Chen, Andrew ^a   Nieman, Marvin T ^a   Adams, Gregory N ^a   LaRusch, Gretchen ^a   Zhou, Yihua ^a   Bilodeau, Matthew L ^d   Mahdi, Fakhri ^e   Warnock, Mark ^f   Schmaier, Alvin H ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

^d Lutheran Medical Office   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; BRADYKININ B2 RECEPTOR; CAPTOPRIL; COLLAGEN; CYCLIC AMP; FIBRINOGEN; GLYCOPROTEIN VI; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NIMESULIDE; NITRIC OXIDE; PADGEM PROTEIN; PROSTACYCLIN; RAMIPRIL; 7 ALA ANGIOTENSIN (1 7); 7-ALA-ANGIOTENSIN (1-7); ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANGIOTENSIN II; ANTITHROMBOCYTIC AGENT; CYCLIC GMP; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTO ONCOGENE PROTEINS C MAS 1; PROTO-ONCOGENE PROTEINS C-MAS-1; SULFONAMIDE;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BONE MARROW TRANSPLANTATION; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; FLOW CYTOMETRY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; 129 MOUSE; ANIMAL; BLOOD; DRUG EFFECT; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; THROMBOSIS; TIME;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLEEDING TIME; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CYCLIC AMP; CYCLIC GMP; EPOPROSTENOL; IMMUNOBLOTTING; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; THROMBOSIS; TIME FACTORS;

MLCS; MLOWN;

EID: 84879451953     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-459156     Document Type: Article

References (35)

1. Yusuf S, Sleight P, Pogue J, et al The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. (Pubitemid 30051645)
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967-1975.
3. Shariat-Madar Z, Mahdi F, Warnock M, et al. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood. 2006;108(1):192-199. (Pubitemid 43990628)
4. Yang HY, Erdös EG. Second kininase in human blood plasma. Nature. 1967;215(5108):1402-1403.
5. Hasan AA, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of a-thrombin-induced platelet activation. Circulation. 1996;94(3):517-528. (Pubitemid 26266140)
6. Hasan AAK, Warnock M, Nieman M, et al. Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol. 2003;285(1):H183-H193. (Pubitemid 36736429)
7. Tan Y, Keum JS, Wang B, et al. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol. 2007;293(4):F1026-F1035. (Pubitemid 47583934)
8. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension. 2003;42(4):600-604. (Pubitemid 37237360)
9. Cervenka L, Harrison-Bernard LM, Dipp S, et al. Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. Hypertension. 1999;34(2):176-180. (Pubitemid 29409211)
10. Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res. 1980;18(6):787-795. (Pubitemid 10036555)
11. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100(14):8258-8263.
12. Fraga-Silva RA, Pinheiro SVB, Gonçalves ACC, et al. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med. 2008;14(1-2):28-35. (Pubitemid 351356883)
13. Knight CG, Morton LF, Peachey AR, et al. The collagen-binding A-domains of integrins alpha(1) beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J Biol Chem. 2000;275(1):35-40. (Pubitemid 30038949)
14. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111(3):315-320. (Pubitemid 40165338)
15. Seyedi N, Xu X, Nasjletti A, et al. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26(1):164-170.
16. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27(3 Pt 2):523-528. (Pubitemid 26086221)
17. Luque M, Martin P, Martell N, et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14(6):799-805. (Pubitemid 26187416)
18. Grobe N, Elased KM, Cool DR, et al. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab. 2012;302(8):E1016-E1024.
19. Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension. 2002;40(5):774-779. (Pubitemid 35278618)
20. Ashby B. Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities. Mol Pharmacol. 1989;36(6):866-873. (Pubitemid 20019558)
21. Coles B, Bloodsworth A, Eiserich JP, et al. Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. J Biol Chem. 2002;277(8):5832-5840. (Pubitemid 34968362)
22. Zhang W, Colman RW. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Blood. 2007;110(5):1475-1482. (Pubitemid 47443962)
23. Loyau S, Dumont B, Ollivier V, et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol. 2012;32(3):778-785.
24. Suzuki H, Murasaki K, Kodama K, et al. Intracellular localization of glycoprotein VI in human platelets and its surface expression upon activation. Br J Haematol. 2003;121(6):904-912. (Pubitemid 36760310)
25. Komine N, Khang S, Wead LM, et al. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis. 2002; 39(1):159-164. (Pubitemid 34062509)
26. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68(5):2189-2196. (Pubitemid 43117793)
27. Fraga-Silva RA, Sorg BS, Wankhede M, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010;16(5-6):210-215.
28. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, et al. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo). 2011;66(5):837-841.
29. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost. 2012;10(2):167-176.
30. Schmaier AA, Zou Z, Kazlauskas A, et al. Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic role. Proc Natl Acad Sci USA. 2009;106(50):21167-21172.
31. Jung SM, Moroi M, Soejima K, et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem. 2012;287(35):30000-30013.
32. Best D, Senis YA, Jarvis GE, et al. GPVI levels in platelets: relationship to platelet function at high shear. Blood. 2003;102(8):2811-2818. (Pubitemid 37248851)
33. -/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1. J Thromb Haemost. 2011;9(2):350-360.
34. Yu Y, Ricciotti E, Scalia R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. www.ScienceTranslationalMedicine.org. 2012;4(132):132ra54.
35. Barbieri SS, Amadio P, Gianellini S, et al. Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a SIRT1- dependent-manner. Circulation. 2012;126(11):1373-1384.